Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway

Abstract Clinical success of the proteasome inhibitor established bortezomib as one of the most effective drugs in treatment of multiple myeloma (MM). While survival benefit of bortezomib generated new treatment strategies, the primary and secondary resistance of MM cells to bortezomib remains a cli...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Li Yang, Jing Chen, Xiaoyan Han, Enfan Zhang, Xi Huang, Xing Guo, Qingxiao Chen, Wenjun Wu, Gaofeng Zheng, Donghua He, Yi Zhao, Yang Yang, Jingsong He, Zhen Cai
Materialtyp: Artikel
Språk:English
Publicerad: Oxford University Press 2018-02-01
Serie:Protein & Cell
Ämnen:
bortezomib
drug resistance
multiple myeloma
NF-κB
Pirh2
Länkar:http://link.springer.com/article/10.1007/s13238-017-0500-9

Internet

http://link.springer.com/article/10.1007/s13238-017-0500-9

Liknande verk